Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities

Ítems similars

• AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity
  per: Karlowsky, James A., et al.
  Publicat: (2009)
• Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252
  per: Parsons, Joshua B., et al.
  Publicat: (2013)
• Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model
  per: Banevicius, Mary A, et al.
  Publicat: (2013)
• Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor
  per: Kaplan, Nachum, et al.
  Publicat: (2012)
• In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics
  per: Kaplan, Nachum, et al.
  Publicat: (2013)